GSK is proud to announce that this week were named one of MIT Technology Review's 2010 TR50--the magazine's first annual list of the 50 most innovative companies in the world. Along with 49 of our peers spanning energy, computing, biomedicine, materials, and the Internet, GSK was evaluated based on our business model, strategies for deploying and scaling up technologies, and the likelihood of success.
Our scientists are working hard to discover new ways of treating and preventing diseases. We recognize that we must improve our ability to deliver medical innovations to address unmet medical needs such as cancer, Alzheimer's and chronic diseases that threaten to overwhelm our healthcare system as our nation's population ages.
Our success depends on a vibrant and productive R&D function. To this end, we have established an innovative R&D structure that encourages creativity and facilitates the accelerated discovery and development of new medicines. We also build collaborations and links with other research groups, biotechnology companies and academic institutions to help develop transformative scientific concepts.
This award acknowledges our work to discover and develop medicines to achieve our mission of helping patients do more, feel better and live longer.
We are honored by the recognition.
For more on the 2010 TR50 visit http://www.technologyreview.com/companywatch/tr50/.